Sarcopenia prevalence. (A) Prevalence of sarcopenia and criteria determining sarcopenia. (B) Sarcopenia according to cancer characteristics including tumor primary origin, grade (WHO), histology, and functionality. (C) Sarcopenia according to the type of previous treatments. Abbreviations: Chemo, chemotherapy; IT, immunotherapy; NEC, neuroendocrine carcinoma; NET neuroendocrine tumors; PRRT, peptine receptor radiotherapy; SSA, somatostatin analogs; TACE, transarterial chemoembolization; TKI, tyrosine kinase inhibitors.